Role of PET/PET–CT in the management of sarcomas

References

• Kumar R, Nadig MR, Chauhan A. Positron emission tomography: clinical applications in oncology. Part 1. Expert Rev. Anticancer Ther.5, 1079–1094 (2005).
   PubMed Web of Science ®Google Scholar
• Jadvar H, Gamie S, Ramanna L, Conti PS. Musculoskeletal system. Semin. Nucl. Med.34, 254–256 (2004).
   PubMed Web of Science ®Google Scholar
• Kumar R, Chauhan A. Positron emission tomography: clinical applications in oncology. Part 2. Expert Rev. Anticancer Ther.6(4), 625–640 (2006).
   PubMed Web of Science ®Google Scholar
• Brisse H, Ollivier L, Edeline V et al. Imaging of malignant tumors of the long bones in children: monitoring response to neoadjuvant chemotherapy and preoperative assessment. Pediatr. Radiol.34, 595–605 (2004).
   PubMedGoogle Scholar
• Garcia R, Kim EE, Wong FC et al. Comparison of fluorine-18-FDG PET and technetium-99m-MIBI SPECT in evaluation of musculoskeletal sarcomas. J. Nucl. Med.37, 1476–1479 (1996).
   PubMed Web of Science ®Google Scholar
• Watanabe H, Shinozaki T, Yanagawa T et al. Glucose metabolic analysis of musculoskeletal tumours using 18fluorine-FDG PET as an aid to preoperative planning. J. Bone Joint Surg. Br.82, 760–767 (2000).
   PubMedGoogle Scholar
• Kern KA, Brunetti A, Norton JA et al. Metabolic imaging of human extremity musculoskeletal tumors by PET. J. Nucl. Med.29, 181–186 (1998).
   Google Scholar
• Feldman F, van Heertum R, Manos C. 18FDG PET scanning of benign and malignant musculoskeletal lesions. Skeletal Radiol.32, 201–208 (2003).
   PubMed Web of Science ®Google Scholar
• Franzius C, Daldrup-Link HE, Sciuk J et al. FDG-PET for detection of pulmonary metastases from malignant primary bone tumors: comparison with spiral CT. Ann. Oncol.12, 479–486 (2001).
   PubMed Web of Science ®Google Scholar
• Franzius C, Sciuk J, Daldrup-Link HE, Jurgens H, Schober O. FDG-PET for detection of osseous metastases from malignant primary bone tumours: comparison with bone scintigraphy. Eur. J. Nucl. Med.27, 1305–1311 (2000).
   PubMedGoogle Scholar
• El-Zeftawy H, Heiba SI, Jana S et al. Role of repeated F-18 fluorodeoxyglucose imaging in management of patients with bone and soft tissue sarcoma. Cancer Biother. Radiopharm.16, 37–46 (2001).
   PubMedGoogle Scholar
• Eary JF, O’Sullivan F, Powitan Y et al. Sarcoma tumor FDG uptake measured by PET and patient outcome: a retrospective analysis Eur. J. Nucl. Med. Mol. Imaging29, 1149–1154 (2002).
   PubMed Web of Science ®Google Scholar
• Franzius C, Sciuk J, Brinkschmidt C, Jurgens H, Schober O. Evaluation of chemotherapy response in primary bone tumors with F-18 FDG positron emission tomography compared with histologically assessed tumor necrosis. Clin. Nucl. Med.25, 874–881 (2000).
   PubMed Web of Science ®Google Scholar
• Wegner EA, Barrington SF, Kingston JE et al. The impact of PET scanning on management of paediatric oncology patients. Eur. J. Nucl. Med. Mol. Imaging32, 23–30 (2005).
   PubMedGoogle Scholar
• Hawkins DS, Rajendran JG, Conrad EU 3rd, Bruckner JD, Eary JF. Evaluation of chemotherapy response in pediatric bone sarcomas by [F-18]-fluorodeoxy-D-glucose positron emission tomography. Cancer94, 3277–3284 (2002). Erratum in: Cancer97, 3130 (2003).
   PubMed Web of Science ®Google Scholar
• Johnson GR, Zhuang H, Khan J, Chiang SB, Alavi A. Roles of positron emission tomography with fluorine-18-deoxyglucose in the detection of local recurrent and distant metastatic sarcoma. Clin. Nucl. Med.28, 815–820 (2003).
   PubMed Web of Science ®Google Scholar
• Franzius C, Daldrup-Link HE, Wagner-Bohn A et al. FDG-PET for detection of recurrences from malignant primary bone tumors: comparison with conventional imaging. Ann. Oncol.13(1), 157–160 (2002).
   PubMed Web of Science ®Google Scholar
• Bredella MA, Caputo GR, Steinbach LS. Value of FDG positron emission tomography in conjunction with MR imaging for evaluating therapy response in patients with musculoskeletal sarcomas. Am. J. Roentgenol.179, 1145–1150 (2002).
   PubMed Web of Science ®Google Scholar
• Kuhelj D, Jereb B. Pediatric osteosarcoma: a 35-year experience in Slovenia. Pediatr. Hematol. Oncol.22, 335–343 (2005).
   PubMed Web of Science ®Google Scholar
• Schulte M, Brecht-Krauss D, Heymer B et al. Grading of tumors and tumorlike lesions of bone: evaluation by FDG PET. J. Nucl. Med.41, 1695–1701 (2000).
   PubMed Web of Science ®Google Scholar
• Franzius C, Bielack S, Flege S, Sciuk J, Jurgens H, Schober O. Prognostic significance of 18F-FDG and 99mTc-methylene diphosphonate uptake in primary osteosarcoma. J. Nucl. Med.43, 1012–1017 (2002).
   PubMed Web of Science ®Google Scholar
• Schulte M, Brecht-Krauss D, Werner M et al. Evaluation of neoadjuvant therapy response of osteogenic sarcoma using FDG PET. J. Nucl. Med.40, 1637–1643 (2000).
   Google Scholar
• Nair N, Ali A, Green AA et al. Response of osteosarcoma to chemotherapy. Evaluation with F-18 FDG-PET scans. Clin. Positron Imaging3, 79–83 (2000).
   PubMedGoogle Scholar
• Gyorke T, Zajic T, Lange A et al. Impact of FDG PET for staging of Ewing sarcomas and primitive neuroectodermal tumours. Nucl. Med. Commun.27, 17–24 (2006).
   PubMed Web of Science ®Google Scholar
• Jiya TU, Wuisman PI. Long-term follow-up of 15 patients with non-metastatic Ewing’s sarcoma and a skip lesion. Acta Orthop.76, 899–903 (2005).
   PubMed Web of Science ®Google Scholar
• Hawkins DS, Schuetze SM, Butrynski JE et al. [18F]Fluorodeoxyglucose positron emission tomography predicts outcome for Ewing sarcoma family of tumors. J. Clin. Oncol.23, 8828–8834 (2005).
   PubMed Web of Science ®Google Scholar
• Aoki J, Watanabe H, Shinozaki T, Tokunaga M, Inoue T, Endo K. FDG-PET in differential diagnosis and grading of chondrosarcomas. J. Comput. Assist. Tomogr.23, 603–608 (1999).
   PubMedGoogle Scholar
• Feldman F, Van Heertum R, Saxena C, Parisien M. 18FDG-PET applications for cartilage neoplasms. Skeletal Radiol.34, 367–374 (2005).
   PubMedGoogle Scholar
• Lee FY, Yu J, Chang SS, Fawwaz R, Parisien MV. Diagnostic value and limitations of fluorine-18 fluorodeoxyglucose positron emission tomography for cartilaginous tumors of bone. J. Bone Joint Surg. Am.86-A, 2677–2685 (2004).
   Google Scholar
• Brenner W, Conrad EU, Eary JF. FDG-PET imaging for grading and prediction of outcome in chondrosarcoma patients. Eur. J. Nucl. Med. Mol. Imaging31, 189–195 (2004).
   PubMed Web of Science ®Google Scholar
• Knapp EL, Kransdorf MJ, Letson GD. Diagnostic imaging update: soft tissue sarcomas. Cancer Control12, 22–26 (2005).
   PubMedGoogle Scholar
• Hain SF, O’Doherty MJ, Bingham J, Chinyama C, Smith MA. Can FDG PET be used to successfully direct preoperative biopsy of soft tissue tumours? Nucl. Med. Commun.24, 1139–1143 (2003).
   PubMed Web of Science ®Google Scholar
• Hicks RJ, Toner GC, Choong PF. Clinical applications of molecular imaging in sarcoma evaluation. Cancer Imaging5, 66–72 (2005).
   PubMedGoogle Scholar
• Schwarzbach MH, Dimitrakopoulou-Strauss A, Willeke F et al. Clinical value of [18-F] fluorodeoxyglucose positron emission tomography imaging in soft tissue sarcomas. Ann. Surg.231, 380–386 (2000).
   PubMed Web of Science ®Google Scholar
• Nieweg OE, Pruim J, van Ginkel RJ et al. Fluorine-18-fluorodeoxyglucose PET imaging of soft-tissue sarcoma. J. Nucl. Med.37, 257–261 (1996).
   PubMedGoogle Scholar
• Tateishi U, Yamaguchi U, Seki K, Terauchi T, Arai Y, Hasegawa T. Glut-1 expression and enhanced glucose metabolism are associated with tumour grade in bone and soft tissue sarcomas: a prospective evaluation by [18F]fluorodeoxyglucose positron emission tomography. Eur. J. Nucl. Med. Mol. Imaging (2006) (In Press).
   Google Scholar
• Schwarzbach MH, Dimitrakopoulou-Strauss A, Mechtersheimer G et al. Assessment of soft tissue lesions suspicious for liposarcoma by F18-deoxyglucose (FDG) positron emission tomography (PET). Anticancer Res.21, 3609–3614 (2001).
   PubMed Web of Science ®Google Scholar
• Eary JF, Conrad EU, Bruckner JD et al. Quantitative [F-18]fluorodeoxyglucose positron emission tomography in pretreatment and grading of sarcoma. Clin. Cancer Res.4, 1215–1220 (1998).
   PubMed Web of Science ®Google Scholar
• Dimitrakopoulou-Strauss A, Strauss LG, Schwarzbach M et al. Dynamic PET 18F-FDG studies in patients with primary and recurrent soft-tissue sarcomas: impact on diagnosis and correlation with grading. J. Nucl. Med.42, 713–720 (2001).
   PubMed Web of Science ®Google Scholar
• Ioannidis JP, Lau J. 18F-FDG PET for the diagnosis and grading of soft-tissue sarcoma: a meta-analysis. J. Nucl. Med.44, 717–724 (2003).
   PubMed Web of Science ®Google Scholar
• Bastiaannet E, Groen H, Jager PL et al. The value of FDG-PET in the detection, grading and response to therapy of soft tissue and bone sarcomas; a systematic review and meta-analysis. Cancer Treat. Rev.30, 83–101 (2004).
   PubMed Web of Science ®Google Scholar
• Kumar R, Loving VA, Chauhan A, Zhuang H, Mitchell S, Alavi A. Potential of dual-time-point imaging to improve breast cancer diagnosis with 18F-FDG PET. J. Nucl. Med.46, 1819–1824 (2005).
   PubMed Web of Science ®Google Scholar
• Kwee SA, Wei H, Sesterhenn I, Yun D, Coel MN. Localization of primary prostate cancer with dual-phase 18F-fluorocholine PET. J. Nucl. Med.47, 262–269 (2006).
   PubMed Web of Science ®Google Scholar
• Zhuang H, Pourdehnad M, Lambright ES et al. Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes. J. Nucl. Med.42, 1412–1417 (2001).
   PubMed Web of Science ®Google Scholar
• Lodge MA, Lucas JD, Marsden PK, Cronin BF, O’Doherty MJ, Smith MA. A PET study of 18FDG uptake in soft tissue masses. Eur. J. Nucl. Med.26, 22–30 (1999).
   PubMedGoogle Scholar
• Hain SF, O’Doherty MJ, Lucas JD, Smith MA. Fluorodeoxyglucose PET in the evaluation of amputations for soft tissue sarcoma. Nucl. Med. Commun.20, 845–848 (1999).
   PubMedGoogle Scholar
• Kole AC, Nieweg OE, van Ginkel RJ et al. Detection of local recurrence of soft-tissue sarcoma with positron emission tomography using 18Ffluorodeoxyglucose. Ann. Surg. Oncol.4, 57–63 (1997).
   PubMed Web of Science ®Google Scholar
• Lucas JD, O’Doherty MJ, Wong JC et al. Evaluation of fluorodeoxyglucose positron emission tomography in the management of soft-tissue sarcomas. J. Bone Joint Surg. Br.80, 441–447 (1998).
   PubMedGoogle Scholar
• Jadvar H, Fischman AJ. Evaluation of rare tumors with F-18fluorodeoxyglucose positron emission tomography. Clin. Positron Imaging2, 153–158 (1999).
   PubMedGoogle Scholar
• Jones DN, McCowage GB, Sostman HD et al. Monitoring of neoadjuvant therapy response of soft-tissue and musculoskeletal sarcoma using fluorine-18-FDG PET. J. Nucl. Med.37, 1438–1444 (1999).
   Google Scholar
• Schuetze SM, Rubin BP, Vernon C et al. Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy. Cancer103, 339–348 (2005).
   PubMed Web of Science ®Google Scholar
• Schwarzbach MH, Hinz U, Dimitrakopoulou-Strauss A et al. Prognostic significance of preoperative 18-F fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging in patients with resectable soft tissue sarcomas. Ann. Surg.241, 286–294 (2005).
   PubMed Web of Science ®Google Scholar
• Stroobants S, Goeminne J, Seegers M et al.18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur. J. Cancer39, 2012–2020 (2003).
   PubMed Web of Science ®Google Scholar
• Goldstein D, Tan BS, Rossleigh M, Haindl W, Walker B, Dixon J. Gastrointestinal stromal tumours: correlation of 18F-FDG γ camera-based coincidence positron emission tomography with CT for the assessment of treatment response – an AGITG study. Oncology69, 326–332 (2005).
   PubMedGoogle Scholar
• Goerres GW, Stupp R, Barghouth G et al. The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate. Eur. J. Nucl. Med. Mol. Imaging32, 153–162 (2005).
   PubMed Web of Science ®Google Scholar
• Schwarzbach M, Willeke F, Dimitrakopoulou-Strauss A et al. Functional imaging and detection of local recurrence in soft tissue sarcomas by positron emission tomography. Anticancer Res.19, 1343–1349 (1999).
   PubMed Web of Science ®Google Scholar
• Cobben DC, Elsinga PH, Suurmeijer AJ et al. Detection and grading of soft tissue sarcomas of the extremities with 18F-3´-fluoro-3´-deoxy-L-thymidine. Clin. Cancer Res.10, 1685–1690 (2004).
   PubMed Web of Science ®Google Scholar
• Plaat B, Kole A, Mastik M, Hoekstra H, Molenaar W, Vaalburg W. Protein synthesis rate measured with L-[1–”C]tyrosine positron emission tomography correlates with mitotic activity and MIB-1 antibody-detected proliferation in human soft tissue sarcomas. Eur. J. Nucl. Med.26, 328–332 (1999).
   PubMedGoogle Scholar
• Yanagawa T, Watanabe H, Inoue T et al. Carbon-11 choline positron emission tomography in musculoskeletal tumors: comparison with fluorine-18 fluorodeoxyglucose positron emission tomography. J. Comput. Assist. Tomogr.27, 175–182 (2003).
   PubMed Web of Science ®Google Scholar